Company intelligence / Profile preview

Abolis Biotechnologies

Évry-Courcouronnes, France

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Abolis Biotechnologies has demonstrated pre-commercial results in development and scaling of novel microbial strains and fermentation processes for high-value ingredient production in sectors including health, cosmetics, nutrition, and chemicals. Products based on its platform technology are expected to reach the market in 2025, with successful industrial collaborations and capacity scaling evident in recent partnerships[1][2][4][6][8].

Modalities: Microbial therapyMicrobial engineeringSynthetic biology platform
Industry: Non-Drug Biotech

Partnerships

HealthTech Bioactives (HTBA)L’OréalEvonikServierBel GroupLesaffre

Beyond the preview

Go deeper on Abolis Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abolis Biotechnologies.

Explore the full profile